Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions •...
Transcript of Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions •...
![Page 1: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/1.jpg)
Poliquistosis renal
Sociedad Norte de Nefrología Bilbao 25-‐26 de Noviembre 2016
![Page 2: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/2.jpg)
![Page 3: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/3.jpg)
60 años. RemiBdo desde otro Hospital con el diagnósBco de ESRD por ADPKD Crs 4 mg/dl
Riñones con múlBples quistes, de 10 cm de eje longitudinal Microhematuria y proteinuria no nefróBca persistente. Varios miembros de la familia con microhematuria, uno de ellos diagnosBcado mediante Biopsia de Enfermedad de la membrana basal delgada
![Page 4: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/4.jpg)
Table 1 Characteristics of the ciliopathies
Kurschat, C. E. et al. (2014) An approach to cystic kidney diseases: the clinician’s view Nat. Rev. Nephrol. doi:10.1038/nrneph.2014.173
![Page 5: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/5.jpg)
![Page 6: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/6.jpg)
![Page 7: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/7.jpg)
![Page 8: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/8.jpg)
Figure 4 Relationship between age and total kidney volume (TKV) in patients with autosomal dominant polycystic kidney disease
Grantham, J. J. & Torres, V. E. (2016) The importance of total kidney volume in evaluating progression of polycystic kidney disease Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.135
Part a reproduced with permission from Massachusetts Medical Society © Jared J. Grantham et al. Volume progression in polycystic kidney disease. N. Engl. J. Med.
354, 2122–2130 (2006). Part b reproduced with permission from PLOS © Dongping Chen. et al. PLoS ONE 9, e92232 (2014), which is licensed under a Creative Commons Attribution 4.0
International Licence. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
![Page 9: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/9.jpg)
Figure 5 Hypothetical inverse relationship between total kidney volume (TKV) and glomerular filtration rate (GFR) in patients with autosomal dominant polycystic kidney disease (ADPKD)
Grantham, J. J. & Torres, V. E. (2016) The importance of total kidney volume in evaluating progression of polycystic kidney disease Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.135
![Page 10: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/10.jpg)
Figure 6 Hypothetical effect of starting therapy for autosomal dominant polycystic kidney disease (ADPKD) at 18 years or 35 years of age
Grantham, J. J. & Torres, V. E. (2016) The importance of total kidney volume in evaluating progression of polycystic kidney disease Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.135
![Page 11: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/11.jpg)
Diagram depicting the spectrum of predictors for rapid renal disease progression in ADPKD. Shaded ovals represent the most established predictors.
Robert W. Schrier et al. JASN 2014;25:2399-2418
©2014 by American Society of Nephrology
![Page 12: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/12.jpg)
![Page 13: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/13.jpg)
§ PROBLEMAS: Dificulta para acceder a ESTUDIO GENÉTICO y alto coste.
![Page 14: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/14.jpg)
Kidney International 2015 88, 146-151DOI: (10.1038/ki.2015.71) Copyright © 2015 International Society of Nephrology Terms and Conditions
![Page 15: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/15.jpg)
Pathogenetic role of RAAS in ADPKD.
Robert W. Schrier JASN 2009;20:1888-1893
1985-1992 a 1992-2001: 〉10 años para desarrollar ERCT.
![Page 16: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/16.jpg)
Original Research |15 November
1991
Reversible Renal Failure Associated with Angiotensin-
Converting Enzyme Inhibitors in Polycystic Kidney Disease
![Page 17: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/17.jpg)
Original Article Angiotensin Blockade in Late Autosomal Dominant
Polycystic Kidney Disease
Vicente E. Torres, M.D., Ph.D., Kaleab Z. Abebe, Ph.D., Arlene B. Chapman, M.D., Robert W. Schrier, M.D., William E. Braun, M.D., Theodore I. Steinman, M.D., Franz T. Winklhofer, M.D., Godela Brosnahan, M.D., Peter G. Czarnecki, M.D., Marie C. Hogan, M.D., Ph.D., Dana C. Miskulin, M.D.,
Frederic F. Rahbari-Oskoui, M.D., Jared J. Grantham, M.D., Peter C. Harris, Ph.D., Michael F. Flessner, M.D., Ph.D., Charity G. Moore, Ph.D., M.S.P.H., Ronald D. Perrone, M.D., for the HALT-PKD Trial Investigators
N Engl J Med Volume 371(24):2267-2276
December 11, 2014
![Page 18: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/18.jpg)
Study Overview
• This trial tested single versus dual inhibition of the renin–angiotensin–aldosterone system in ADPKD.
• ACE-inhibitor monotherapy controlled blood pressure in most patients. • Adding an angiotensin II–receptor blocker did not alter the decline in
estimated GFR.
![Page 19: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/19.jpg)
Effect of Lisinopril–Telmisartan, as Compared with Lisinopril–Placebo, on the Time to Primary-Outcome Events and on the Estimated Glomerular Filtration Rate (eGFR).
Torres VE et al. N Engl J Med 2014;371:2267-2276
![Page 20: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/20.jpg)
Original Article Blood Pressure in Early Autosomal Dominant
Polycystic Kidney Disease
Robert W. Schrier, M.D., Kaleab Z. Abebe, Ph.D., Ronald D. Perrone, M.D., Vicente E. Torres, M.D., Ph.D., William E. Braun, M.D., Theodore I.
Steinman, M.D., Franz T. Winklhofer, M.D., Godela Brosnahan, M.D., Peter G. Czarnecki, M.D., Marie C. Hogan, M.D., Ph.D., Dana C. Miskulin, M.D.,
Frederic F. Rahbari-Oskoui, M.D., Jared J. Grantham, M.D., Peter C. Harris, Ph.D., Michael F. Flessner, M.D., Ph.D., Kyongtae T. Bae, M.D.,
Charity G. Moore, Ph.D., M.S.P.H., Arlene B. Chapman, M.D., for the HALT-PKD Trial Investigators
N Engl J Med Volume 371(24):2255-2266
December 11, 2014
![Page 21: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/21.jpg)
Enrollment, Randomization, and Follow-up of the Study Participants.
Schrier RW et al. N Engl J Med 2014;371:2255-2266
![Page 22: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/22.jpg)
Changes in Total Kidney Volume and Estimated Glomerular Filtration Rate (eGFR) during Follow-up and Subgroup Analyses, According to Blood-Pressure Group.
Schrier RW et al. N Engl J Med 2014;371:2255-2266
![Page 23: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/23.jpg)
Changes in Total Kidney Volume and eGFR during Follow-up, and Subgroup Analyses, According to Treatment Group.
Schrier RW et al. N Engl J Med 2014;371:2255-2266
![Page 24: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/24.jpg)
Conclusions
• In early ADPKD, the combination of lisinopril and telmisartan did not significantly alter the rate of increase in total kidney volume.
• As compared with standard blood-pressure control, rigorous blood-pressure control was associated with a slower increase in total kidney volume, no overall change in the estimated GFR, a greater decline in the left-ventricular-mass index, and greater reduction in urinary albumin excretion.
![Page 25: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/25.jpg)
N Engl J Med 2010; 363: 830-‐841
N= 399
§ FG: 30-‐89 ml/min y >90. Vol> 1000 ml.
§ Volumen 2 años: 230 ml vs 310; p 0.06.
§ FG: -‐ 8.9 ml/min/y vs -‐7.7 p< 0.15.
§ Más efectos 2ª en grupo io.
![Page 26: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/26.jpg)
Original Article Sirolimus and Kidney Growth in Autosomal
Dominant Polycystic Kidney Disease
Andreas L. Serra, M.D., Diane Poster, M.D., Andreas D. Kistler, M.D., Fabienne Krauer, B.S., Shagun Raina, M.S., James Young, Ph.D., Katharina M. Rentsch, Ph.D., Katharina S. Spanaus, M.D., Oliver Senn, M.D., M.P.H., Paulus Kristanto, Ph.D., Hans
Scheffel, M.D., Dominik Weishaupt, M.D., and Rudolf P. Wüthrich, M.D.
N Engl J Med Volume 363(9):820-829
August 26, 2010
![Page 27: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/27.jpg)
Total Kidney Volume
Serra AL et al. N Engl J Med 2010;363:820-829
![Page 28: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/28.jpg)
Study flow diagram.
Piero Ruggenenti et al. CJASN 2016;11:785-794
![Page 29: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/29.jpg)
GFR changes during the study according to treatment groups.
Piero Ruggenenti et al. CJASN 2016;11:785-794
©2016 by American Society of Nephrology
![Page 30: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/30.jpg)
Individual patient total kidney values at baseline and 12 months of follow-up according to treatment groups.
Piero Ruggenenti et al. CJASN 2016;11:785-794
©2016 by American Society of Nephrology
![Page 31: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/31.jpg)
Changes in twenty-four–hour albuminuria and proteinuria during the study according to treatment groups.
Piero Ruggenenti et al. CJASN 2016;11:785-794
![Page 32: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/32.jpg)
Original Article Tolvaptan in Patients with Autosomal Dominant
Polycystic Kidney Disease
Vicente E. Torres, M.D., Ph.D., Arlene B. Chapman, M.D., Olivier Devuyst, M.D., Ph.D., Ron T. Gansevoort, M.D., Ph.D., Jared J. Grantham, M.D., Eiji Higashihara, M.D., Ph.D., Ronald D. Perrone, M.D., Holly B. Krasa, M.S., John Ouyang, Ph.D., Frank S. Czerwiec, M.D., Ph.D., for the TEMPO 3:4
Trial Investigators
N Engl J Med Volume 367(25):2407-2418
December 20, 2012
![Page 33: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/33.jpg)
Patient Enrollment and Outcomes.
Torres VE et al. N Engl J Med 2012;367:2407-2418
![Page 34: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/34.jpg)
Effect of Tolvaptan on the Annual Slopes of Total Kidney Volume and Kidney Function.
Torres VE et al. N Engl J Med 2012;367:2407-2418
![Page 35: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/35.jpg)
Effect of Tolvaptan on the Time to Multiple Events Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Torres VE et al. N Engl J Med 2012;367:2407-2418
![Page 36: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/36.jpg)
Most Common Adverse Events and Serious Adverse Events.
Torres VE et al. N Engl J Med 2012;367:2407-2418
![Page 37: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/37.jpg)
Conclusions
• Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events.
![Page 38: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/38.jpg)
![Page 39: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/39.jpg)
§ Estudio randomizado doble-‐ciego. PravastaBna 20-‐40 mg frente a placebo.
§ Mecanismo fisiopatológico desconocido.
§ 8-‐22 años. 3 años de seguimiento.
![Page 40: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/40.jpg)
73 ENSAYOS EN MARCHA EN ADPKD
![Page 41: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/41.jpg)
Markers used to assess prognosis in ADPKD. Shaded rectangles represent the best-validated markers (adapted from ref. [24]).
Ron T. Gansevoort et al. Nephrol. Dial. Transplant. 2016;31:337-348
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
![Page 42: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/42.jpg)
![Page 43: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/43.jpg)
The Mayo classification for prediction of disease progression in ADPKD by htTKV and age.
Ron T. Gansevoort et al. Nephrol. Dial. Transplant. 2016;31:337-348
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
![Page 44: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/44.jpg)
![Page 45: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/45.jpg)
![Page 46: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/46.jpg)
Algorithm to assess indications for initiation of treatment in ADPKD. The EMA label for tolvaptan states that this drug is indicated for ‘ADPKD patients with CKD stages 1–3 and
evidence of rapid disease progression at initiation of treatment’.
Ron T. Gansevoort et al. Nephrol. Dial. Transplant. 2016;31:337-348
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
![Page 47: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/47.jpg)
CÓMO INICIAR, TITULAR Y MANTENER EL TRATAMIENTO CON TOLVAPTÁN?
§ El inicio de Tolvaptán se suele acompañar de una “caída” del eGFR (tras 3 semanas con 120 mg: -‐0.7-‐7.8 ml/min ≈ al observado con IECA/ARA II). § No hay marcadores a corto plazo que hablen de la eficacia del tratamiento. § Ensayar como en los estudios (30/15; 45/15; 60/30; 90/30 mg). § TEMPO 3:4: 55%-‐120 mg; 21%-‐90 mg; 24%-‐60 mg-‐-‐ ✗: 95 mg. § 23% abandonaron el estudio por efectos 2º (7.4% por efectos diueréBcos-‐1º tres meses).
Irazabal MV, Kidney Int 2011;80: 295-‐301
Rapid decrease in cys9c fluid secre9on 3 SEMANAS DE TRATAMIENTO
![Page 48: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/48.jpg)
-‐ 49% -‐26%
![Page 49: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/49.jpg)
“A phase 3b, mul?-‐center, randomized-‐withdrawal, placebo-‐controlled, double-‐blind, parallel-‐group trial to compare the efficacy and safety of Tolvaptan (45-‐120 mgday, split dose) in subjects with chronic kidney disease between late Stage 2 to
early Stage 4 due to Autosomal Dominant Polycys?c Kidney Disease”
CRITERIOS DE INCLUSIÓN: § Hombres o mujeres entre 18-‐55 años con eGFR: 25-‐65 ml/min ó
§ Hombres o mujeres entre 56-‐65 años con eGFR: 25-‐44 ml/min.
§ No toma previa de Tolvaptán.
§ DiagnósBco de ADPKD por los criterios modificados de Pei-‐Ravine.
CRITERIOS DE EXCLUSIÓN: § Mujeres embarazadas o que no quieran adoptar medidas anBconcepBvas. § Necesidad de uso crónico de diuréBcos. § Enfermedad hepáBca o alteración del perfil hepáBco. § Pacientes con DM avanzada (proteinuria significaBva, reBnopava, nefropava) con HbA1c> 7.5%.
![Page 50: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/50.jpg)
“A phase 3b, mul?-‐center, randomized-‐withdrawal, placebo-‐controlled, double-‐blind, parallel-‐group trial to compare the efficacy and safety of Tolvaptan (45-‐120 mgday, split dose) in subjects with chronic kidney disease between late Stage 2 to
early Stage 4 due to Autosomal Dominant Polycys?c Kidney Disease”
² 1.300 pacientes en 220 centros.
² Duración: 12 meses, 6 semanas de Btulación de dosis (30/15; 45/15; 60/30; 90/30 mg). Duración total de 15-‐17 meses.
² Primary Efficacy Endpoint: Cambios en eGFR pre y post-‐tratamiento.
² Secondary Endpoints: Slope anual de eGFR.
² Estudios de seguridad.
![Page 51: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/51.jpg)
![Page 52: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/52.jpg)
![Page 53: Sociedad)Norte)de)Nefrología Bilbao)25926)de)Noviembre)2016) · 2016. 11. 29. · Conclusions • In early ADPKD, the combination of lisinopril and telmisartan did not significantly](https://reader034.fdocuments.es/reader034/viewer/2022051904/5ff65e9991db050b9076f3a4/html5/thumbnails/53.jpg)